Nos membres
| Location: | Ottawa, Ontario |
|---|---|
| Industry Sector: | Professional Services and Consulting |
| Website: | http://3sixtypublicaffairs.com/welcome/ |
| Contact: |
Bill Dempster (wdempster@3sixtypublicaffairs.com) 1 613 800.8340 |
| Description: | 3Sixty is a government relations and public policy consulting firm based in Ottawa, Canada, serving the agri-food, consumer products, health and life sciences sectors. We strive to bridge differences between how governments, stakeholders and businesses communicate and make decisions. Drawing on our business and government experience, 3Sixty provides industry-leading advice and counsel with integrity, commitment and top-notch client service. |
| Location: | Saint-Laurent, Quebec |
|---|---|
| Industry Sector: | Pharma |
| Website: | abbott.ca |
| Contact: |
Dirk van Eeden (dirk.vaneeden@abbott.com) 1 514 8327000 |
| Ownership: | Subsidiary - New York Stock Exchange (NYSE): ABT |
| Description: | Abbott Canada is an affiliate of Abbott and the first international office to be established. Today Abbott Canada employs some 2,000 individuals across the country with more than 300 based out of their headquarters in the Montreal borough of Ville Saint-Laurent. |
| Location: | Saskatoon, Saskatchewan |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Contact: |
Sanj Singh (sanj@adetherapeutics.com) 1 306 2615189 |
| Description: | AdeTherapeutics is a privately-held clinical-stage drug development company. Their vision is to be world wide leader in developing products that deal with complications related to surgery. AdeTherapeutics has a robust portfolio of high value products by developing clinical-stage ready therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages (i.e. Phase II trials). |
| Location: | Washington, District Of Columbia |
|---|---|
| Industry Sector: | Biotechnology / R&D Services |
| Website: | www.adjuvant.com |
| Contact: |
Jeff Conroy (jxc@adjuvant.com) 1 301 8306290 |
| Description: | Adjuvant Partners is a life sciences transaction advisory company representing a portfolio of small-mid cap firms with clinical and pre-clincial programs in cardiovascular disease, oncology, neuro-degenerative disorders, addiction, and infectious disease. They also work with large and specialty pharma clients on various in-licensing projects with an emphasis on infectious disease, CNS disorders, pain, and oncology. Their team has experience working in successful public and start-up firms in the life science, healthcare, and technology markets. They have a unique perspective of today's markets and trends, which has enabled us to identify unmet needs, invigorate established products, create profitable alliances, and launch new ventures. |
| Location: | Toronto, Ontario |
|---|---|
| Industry Sector: | Pharma |
| Website: | www.afnm.com |
| Contact: |
Owen Roberts (oroberts@afnm.com) 1 416 6456613 |
| Description: | Affinium is a specialty pharmaceutical company focused on the development of novel antibacterial medicines. Affinium's FASII antibacterial programs constitute a new antibiotic franchise with the potential for multiple products. Their lead molecule, AFN-1252, is a very well tolerated, highly-potent antibiotic targeting all strains of Staphylococcus including MRSA. Oral and IV formulations are in development. A Phase 2 study with the oral formulation began in January 2012. IV is undergoing IND-enabling work. Affinium are seeking a global development and licensing partner. |
| Location: | Ottawa, Ontario |
|---|---|
| Industry Sector: | Public / Non-Profit Organizations |
| Website: | www.aic.ca |
| Contact: |
Myles Frosst (mfrosst@aic.ca) 1 613 2329459 |
| Description: | The Agricultural Institute of Canada exists to build scientific capacity for the sustainable and profitable optimization of societal benefits that can be derived from the agro-economy. The agro-economy consists of all knowledge chains (from basic and applied research to innovation, commercialization and technology transfer) and all value chains that rely upon or focus upon agricultural output as a major input to final products. |
| Location: | Ottawa, Ontario |
|---|---|
| Industry Sector: | Biotechnology - other |
| Website: | www.agrisoma.com |
| Contact: |
Steven F. Fabijanski (sfabijanski@agrisoma.com) 1 613 8345265 |
| Description: | Agrisoma Biosciences Inc. is a private agricultural biotechnology company using its leading edge ETL technology to create new crop varieties engineered for high-value applications such as biofuel production. |
| Location: | Saskatoon, Saskatchewan |
|---|---|
| Industry Sector: | Public / Non-Profit Organizations |
| Website: | www.agwest.sk.ca |
| Contact: |
Wilf Keller (wilf.keller@agwest.sk.ca) 1 306 975 1939 |
| Description: | Ag-West Bio Inc. is a member-based business development organization in the bioscience sector. We are a not-for-profit organization, funded by Saskatchewan’s Ministry of Agriculture and Agriculture & Agri-Food Canada's Growing Forward program. The company was created in 1989 as Ag-West Biotech and renamed Ag-West Bio in 2004. Ag-West Bio member companies include research organizations, industry (from SMEs to multinationals), research support organizations, economic development organizations and commodity groups. Members represent the biotechnology, bioproducts and biofuels, and health and nutrition sectors. Ag-West Bio is a catalyst for Saskatchewan’s bioeconomy, helping to move research to market. Entrepreneurs commercializing their innovations can come to Ag-West Bio for pathfinding and help creating a sound business plan. We collaborate with the Raj Manek Mentorship program, matching protégés with experienced mentors. Our commercialization fund has assisted many early stage companies, as well as enabling established companies expand their businesses. By hosting numerous networking events, conferences and seminars, we help our community stay connected and informed. We lead delegations to relevant conferences, such as BIO International, and help set up meetings for incoming delegations interested in doing business or finding research partners in Saskatchewan. Ag-West Bio also participates with like-minded companies from across Canada in creating awareness of the industry for the government. If you are a life science innovator or investor, contact Ag-West Bio. www.agwest.sk.ca |
| Location: | Toronto, Ontario |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.aimtherapeutics.com |
| Contact: |
Frank Gleeson (fgleeson@aimtherapeutics.com) 1 647 237 3691 |
| Description: | AIM is a drug development company focused on respiratory diseases. They are developing a novel class of patented non-steroidal, immune modulating drug candidates which exhibit potent anti-inflammatory effects and a favourable safety profile in numerous animal models of disease. |
| Location: | Montreal, Quebec |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.alethiabio.com |
| Contact: |
Yves Cornellier (info@alethiabio.com) 1 514 858 7666 |
| Description: | Alethia Biotherapeutics is engaged in the discovery of novel targets and development of targeted therapeutics. The company has prioritized the development of monoclonal antibodies against novel clinically relevant targets identified using its STAR target discovery platform. |
| Location: | Cheshire, Connecticut |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.alxn.com |
| Contact: |
Irving Adler (clinicaltrials@alxn.com) 1 203 2722596 |
| Ownership: | Public - NASDAQ: ALXN |
| Description: | Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic and kidney diseases, neurologic disorders, ophthalmic, transplant, other inflammatory disorders, and cancer. |
| Location: | Vancouver, British Columbia |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.allontherapeutics.com |
| Contact: |
Rick Smith (info@allontherapeutics.com) 1 604 7360634 |
| Ownership: | Public - Toronto Stock Exchange (TSX): NPC.TO |
| Description: | Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on bringing to market innovative central nervous system therapies. Allon’s lead drug, davunetide, is proceeding in a fully enrolled pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA). This pivotal trial is based upon statistically significant human efficacy demonstrated in amnestic mild cognitive impairment, cognitive impairment associated with schizophrenia, and positive biomarker data. |
| Location: | Mississauga, Ontario |
|---|---|
| Industry Sector: | Pharma |
| Website: | www.amgen.ca |
| Contact: |
Natasha Bond (natashab@amgen.com) 1 905 2853000 |
| Ownership: | Subsidiary - NASDAQ: AMGN |
| Description: | Amgen Canada applies science and innovation to help fight serious illness and dramatically improve people's lives. Amgen contributes to the development of new therapies or new uses for existing medicines in partnership with many of Canada's leading healthcare, academic, research, government, and patient organizations. |
| Location: | Mississauga, Ontario |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.amorfix.com/ |
| Contact: |
James Parsons (james.parsons@amorfix.com) 1 416 8476898 |
| Ownership: | Public - Toronto Stock Exchange (TSX): AMF |
| Description: | Amorfix Life Sciences Ltd. (TSX:AMF) is a product development company creating therapeutic products and diagnostic devices targeting misfolded protein diseases including Alzheimer's disease (AD), cancer and ALS. Amorfix utilizes it computational discovery platform, ProMIS, to predict novel Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Amorfix's lead programs include therapeutics and companion diagnostics for cancers, antibodies and vaccines to DSEs in ALS and AD diagnostic tests. In addition, Amorfix's proprietary Epitope Protection technology enables the specific identification and mearurement of very low levels of misfolded proteins in a biological sample. The Company's diagnostic programs include an ultrasensitive method for the detection of aggregated beta-Amyloid in brain tissue, CSF and blood from animal models of AD, months prior to observable amyloid formation, and development of a predictive screening test for AD. |
| Location: | Montreal, Quebec |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.angiochem.com |
| Contact: |
Catherine Gagnon (cgagnon@angiochem.com) 1 514 7887800 |
| Description: | Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new EPiC compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB. Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including brain cancer, neurodegenerative and lysosomal storage diseases, pain, and others. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. |
| Location: | Vancouver, British Columbia |
|---|---|
| Industry Sector: | Medical Technology |
| Website: | www.angiotech.com |
| Contact: |
K. Thomas Bailey (ir@angio.com) 1 604 221 7676 |
| Ownership: | Public - Tokyo Stock Exchange (TSE): ANPIQ.PK |
| Description: | Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury. |
| Location: | St. John's, Newfoundland |
|---|---|
| Industry Sector: | Biotechnology - other |
| Website: | www.aquabounty.com |
| Contact: |
David A. Frank (investors@aquabounty.com) 1 709 738-4638 |
| Ownership: | Subsidiary - : |
| Description: | Aqua Bounty Technologies is a biotechnology company focused on improving productivity in commercial aquaculture. |
| Location: | Richmond, British Columbia |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.aqxpharma.com |
| Contact: |
Kamran Alam (info@aqxpharma.com) 1 604 629 9223 |
| Description: | Aquinox Pharmaceuticals is a private, venture-backed biopharmaceutical company committed to the discovery, development and commercialization of novel and targeted small molecule therapeutics for the treatment of inflammatory disease and cancer. |
| Location: | San Fransisco, California |
|---|---|
| Industry Sector: | Professional Services and Consulting |
| Website: | www.arnoldporter.com |
| Contact: |
Todd Lorenz (Todd.lorenz@aporter.com) 1 415 356.3000 |
| Description: | Arnold & Porter LLP's San Francisco office provides the firm's clients with sophisticated advice and representation, with particular emphasis on complex commercial litigation, securing and enforcing intellectual property rights, environmental compliance and litigation, and antitrust litigation. |
| Location: | Quebec, Quebec |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.asmacure.com |
| Contact: |
Martin J. Driscoll (martin.driscoll@asmacure.com) 1 418 780 4255 |
| Description: | Asmacure Ltée is focused on the development of nicotinic receptor modulators for the treatment of inflammatory diseases. Their lead compound, ASM-024, is the first nicotinic receptor modulator to enter clinical testing for the treatment of asthma. |
| Location: | Mississauga, Ontario |
|---|---|
| Industry Sector: | Pharma |
| Website: | www.astrazeneca.ca |
| Contact: |
Nicklas Westerholm (IR@astrazeneca.com) 1 905 277 7111 |
| Ownership: | Subsidiary - : |
| Description: | AstraZeneca Canada is an operating subsidiary of a global research based pharmaceutical company. Currently they are most interested in talking with companies that have products that are in pre-registration, registered and/or currently marketed. |
| Location: | Edmonton, Alberta |
|---|---|
| Industry Sector: | Biotechnology / R&D Services |
| Website: | www.atgcell.com |
| Contact: |
(info@atgcell.com) 1 780 450 5519 |
| Description: | ATGCell Inc specializes in the development, production and marketing of recombinant proteins and stably expressing mammalian cell lines for life science researchers and pharmaceutical companies, using state-of-the-art expression and purification platform, and stable cell line generation system. |
| Location: | North Vancouver, British Columbia |
|---|---|
| Industry Sector: | Medical Technology |
| Website: | www.augurex.com |
| Contact: |
Norma K. Biln 1 778 839 3319 |
| Description: | Augurex Life Sciences Corp. develops biomarkers, which are substances that indicate what is going on in the body, thereby making them useful for diagnosing and managing patients’ diseases through the use of simple blood tests. |
| Location: | Malvern, Victoria |
|---|---|
| Industry Sector: | Public / Non-Profit Organizations |
| Website: | www.ausbiotech.org |
| Contact: |
Anna Lavelle (admin@ausbiotech.org) 61 3 98281404 |
| Description: | AusBiotech is Australia's biotechnology industry organisation, which represents over 3,000 members, covering the human health, agricultural, medical device, bioinformatics, environmental and industrial sectors in biotechnology. AusBiotech is dedicated to the development, growth and prosperity of the Australian Biotechnology Industry, by providing initiatives to drive sustainability and growth, outreach and access to markets, and representation and support for members nationally and around the world. AusBiotech has representation in each Australian state providing a national network to support members and promote the commercialisation of Australian bioscience in the national and international marketplaces. Their membership base includes biotechnology companies, ranging from start-ups to mature multinationals, research institutes and universities, specialist service professionals, corporate, institutional, individual and student members from Australia and overseas. |
| Location: | Mississauga, Ontario |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.baxter.ca |
| Contact: |
Saurabh Popat (saurabh_popat@baxter.com) 1 905 369 6000 |
| Ownership: | Subsidiary - : |
| Description: | Baxter Corporation (Canada), a subsidiary of Baxter International Inc. manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. |
